EcoDrugPlus

Protein-Serine O-Palmitoleoyltransferase Porcupine-Like

Ensembl ID : ENSDCDG00000023156
Gene Symbol: LOC114797603
3 Cross references
195 Possible Orthologues:

Protein-Tyrosine Kinase 6-Like

Ensembl ID : ENSDCDG00000035268
Gene Symbol: LOC114798542
2 Cross references
109 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src-Like

Ensembl ID : ENSDCDG00000017389
Gene Symbol: LOC114797789
3 Cross references
198 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSDCDG00000026105
Gene Symbol: P2RX3
3 Cross references
201 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSDCDG00000027907
Gene Symbol: P2RY1
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSDCDG00000031234
Gene Symbol: P2RY2
1 Cross references
200 Possible Orthologues:

Putative Transcription Factor P65 Homolog

Ensembl ID : ENSDCDG00000017742
Gene Symbol: LOC114789171
3 Cross references
201 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSDCDG00000029730
Gene Symbol: P2RY4
3 Cross references
168 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSDCDG00000031254
Gene Symbol: P2RY6
3 Cross references
183 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSDCDG00000006406
Gene Symbol: RAMP1
1 Cross references
190 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSDCDG00000001668
Gene Symbol: RAMP1
3 Cross references
183 Possible Orthologues:

Receptor Activity-Modifying Protein 1-Like

Ensembl ID : ENSDCDG00000035141
Gene Symbol: LOC114769897
3 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).